Trastuzumab Plus Vinorelbine May Be an Effective Alternative for HER2-Positive Breast Cancer

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal Current Oncology, trastuzumab and vinorelbine is an effective alternative to standard taxane-based chemotherapy for patients with early stage or locally advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Researchers at Jewish General Hospital in Montreal, Quebec, Canada, sought to investigate through a retrospective analysis whether trastuzumab plus vinorelbine is a viable alternative to a taxane plus an anthracycline. Some patients refuse to this standard backbone of chemotherapy regimens for patients with HER2-positive breast cancer because of its common adverse effect of alopecia. In addition, some patients may have a contraindication to receive either of those drugs.

For the study, researchers identified 46 patients with a mean age of 64 years who received trastuzumab plus vinorelbine beetween 2003 and 2010. Most patients received the combination therapy weekly for 6 months, followed by trastuzumab alone for 6 months. Results showed a median 5-year overall survival rate of 94% and a median 5-year cancer-specific survival rate of 98%.

One patient died as a result of febrile neutropenia-induced sepsis. The most common grade 3 or 4 adverse effects included neutropenia, febrile neutropenia, fatigue, and anemia.

For EGFR-Mutant Non-Squamous Non-Small Cell Lung Cancer, Bevacizumab Plus Chemotherapy Not Effective
Trastuzumab and vinorelbine an effective alternative to standard chemo.
The authors report the institutional experience with trastuzumab and vinorelbine (tv), a combination with good clinical activity and a good side effect profile for patients with her2–positive breast cancer. For patients with non–metastatic breast cancer refusing alopecia, or for patients who are not candidates for standard chemotherapy, tv is a reasonable alternative to standard adjuvant chemotherapy.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs